These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KANSAS | 45-4082531 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 100 Commercial Street, Atchison Kansas | 66002 |
| (Address of principal executive offices) | (Zip Code) |
|
Quarter ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Sales
|
$ | 88,718 | $ | 88,430 | ||||
|
Less: excise taxes
|
2,314 | 2,086 | ||||||
|
Net sales
|
86,404 | 86,344 | ||||||
|
Cost of sales (a)
|
79,175 | 80,765 | ||||||
|
Gross profit
|
7,229 | 5,579 | ||||||
|
Selling, general and administrative expenses
|
5,875 | 7,748 | ||||||
|
Other operating costs and losses on sale of assets
|
58 | 74 | ||||||
|
Income (loss) from operations
|
1,296 | (2,243 | ) | |||||
|
Gain on sale of joint venture interest
|
- | 4,055 | ||||||
|
Interest income
|
6 | 2 | ||||||
|
Interest expense
|
(289 | ) | (255 | ) | ||||
|
Equity in earnings (loss)
|
(942 | ) | 437 | |||||
|
Income from continuing operations before income taxes
|
71 | 1,996 | ||||||
|
Provision for income taxes
|
- | 120 | ||||||
|
Net income from continuing operations
|
71 | 1,876 | ||||||
|
Discontinued operations, net of tax (Note 9)
|
1,406 | - | ||||||
|
Net income
|
1,477 | 1,876 | ||||||
|
Other comprehensive income (loss), net of tax
|
(149 | ) | 173 | |||||
|
Comprehensive income
|
$ | 1,328 | $ | 2,049 | ||||
|
Basic and diluted earnings per share
|
||||||||
|
Income from continuing operations
|
$ | - | $ | 0.10 | ||||
|
Income from discontinued operations
|
0.08 | - | ||||||
|
Net income
|
$ | 0.08 | $ | 0.10 | ||||
|
Dividends per common share
|
$ | 0.05 | $ | 0.05 | ||||
|
(a)
|
Includes related party purchases of $3,491 and $16,226 for the quarters ended March 31, 2013 and 2012, respectively. See
Note 2. Equity Method Investments
.
|
|
March 31,
2013
|
December 31,
2012
|
|||||||
|
Current Assets
|
||||||||
|
Restricted cash
|
$ | - | $ | 12 | ||||
|
Receivables (less allowance for doubtful accounts:
March 31, 2013 - $20; December 31, 2012 - $12)
|
34,345 | 35,325 | ||||||
|
Inventory
|
38,998 | 36,532 | ||||||
|
Prepaid expenses
|
1,351 | 697 | ||||||
|
Deferred income taxes
|
5,044 | 5,283 | ||||||
|
Refundable income taxes
|
280 | 242 | ||||||
|
Total current assets
|
80,018 | 78,091 | ||||||
|
Property and equipment
|
188,764 | 190,519 | ||||||
|
Less accumulated depreciation and amortization
|
(116,227 | ) | (115,128 | ) | ||||
|
Property and equipment, net
|
72,537 | 75,391 | ||||||
|
Equity method investments
|
6,347 | 7,301 | ||||||
|
Other noncurrent assets
|
2,312 | 2,388 | ||||||
|
Total assets
|
$ | 161,214 | $ | 163,171 | ||||
|
Current Liabilities
|
||||||||
|
Current maturities of long-term debt
|
$ | 1,642 | $ | 1,683 | ||||
|
Accounts payable
|
22,977 | 18,860 | ||||||
|
Accounts payable to affiliate, net
|
721 | 4,008 | ||||||
|
Accrued expenses
|
6,677 | 5,220 | ||||||
|
Total current liabilities
|
32,017 | 29,771 | ||||||
|
Long-term debt, less current maturities
|
4,783 | 5,168 | ||||||
|
Revolving credit facility
|
21,766 | 25,893 | ||||||
|
Deferred credit
|
4,036 | 4,133 | ||||||
|
Accrued retirement health and life insurance benefits
|
4,985 | 5,096 | ||||||
|
Other noncurrent liabilities
|
1,006 | 1,000 | ||||||
|
Deferred income taxes
|
5,044 | 5,283 | ||||||
|
Total liabilities
|
73,637 | 76,344 | ||||||
|
Commitments and Contingencies – See Note 4
|
||||||||
|
Stockholders’ Equity
|
||||||||
|
Capital stock
|
||||||||
|
Preferred, 5% non-cumulative; $10 par value; authorized 1,000
shares; issued and outstanding 437 shares
|
4 | 4 | ||||||
|
Common stock
|
||||||||
|
No par value; authorized 40,000,000 shares; issued 18,115,965
shares at March 31, 2013 and December 31, 2012,
17,914,119 and 17,934,233 shares outstanding at March 31,
2013 and December 31, 2012, respectively
|
6,715 | 6,715 | ||||||
|
Additional paid-in capital
|
8,247 | 7,894 | ||||||
|
Retained earnings
|
73,092 | 72,531 | ||||||
|
Accumulated other comprehensive loss
|
(382 | ) | (233 | ) | ||||
|
Treasury stock, at cost
|
||||||||
|
201,846 and 181,732 shares at March 31, 2013 and December 31, 2012, respectively
|
(99 | ) | (84 | ) | ||||
|
Total stockholders’ equity
|
87,577 | 86,827 | ||||||
|
Total liabilities and stockholders’ equity
|
$ | 161,214 | $ | 163,171 | ||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Cash Flows from Operating Activities
|
||||||||
|
Net income
|
$ | 1,477 | $ | 1,876 | ||||
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
||||||||
|
Depreciation and amortization
|
2,968 | 2,935 | ||||||
|
Gain on sale of bioplastics manufacturing business
|
(1,453 | ) | - | |||||
|
Gain on sale of joint venture interest
|
- | (4,055 | ) | |||||
|
Loss on sale of assets
|
- | 48 | ||||||
|
Share based compensation
|
353 | 353 | ||||||
|
Equity in (earnings) loss
|
942 | (437 | ) | |||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Restricted cash
|
12 | 1,454 | ||||||
|
Receivables, net
|
980 | (7,984 | ) | |||||
|
Inventory
|
(2,539 | ) | (3,236 | ) | ||||
|
Prepaid expenses
|
(654 | ) | (409 | ) | ||||
|
Refundable income taxes
|
(38 | ) | 120 | |||||
|
Accounts payable
|
3,603 | (1,880 | ) | |||||
|
Accounts payable to affiliate, net
|
(3,287 | ) | (1,380 | ) | ||||
|
Accrued expenses
|
529 | 904 | ||||||
|
Change in derivatives
|
- | 1,131 | ||||||
|
Deferred credit
|
(97 | ) | (150 | ) | ||||
|
Accrued retirement health and life insurance benefits and other noncurrent liabilities
|
(242 | ) | (261 | ) | ||||
|
Net cash provided by (used in) operating activities
|
2,554 | (10,971 | ) | |||||
|
Cash Flows from Investing Activities
|
||||||||
|
Proceeds from sale of bioplastics manufacturing business
|
2,797 | - | ||||||
|
Proceeds from sale of joint venture interest
|
- | 9,103 | ||||||
|
Proceeds from the disposition of property and equipment
|
- | 2,232 | ||||||
|
Additions to property and equipment
|
(798 | ) | (484 | ) | ||||
|
Investment in and advances to unconsolidated subsidiaries
|
- | (500 | ) | |||||
|
Net cash provided by investing activities
|
1,999 | 10,351 | ||||||
|
Cash Flows from Financing Activities
|
||||||||
|
Principal payments on long-term debt
|
(426 | ) | (413 | ) | ||||
|
Proceeds from revolving credit facility
|
28,850 | 43,756 | ||||||
|
Principal payments on revolving credit facility
|
(32,977 | ) | (43,106 | ) | ||||
|
Net cash provided by (used by) financing activities
|
(4,553 | ) | 237 | |||||
|
Decrease in cash and cash equivalents
|
- | (383 | ) | |||||
|
Cash and cash equivalents, beginning of year
|
- | 383 | ||||||
|
Cash and cash equivalents, end of period
|
$ | - | $ | - | ||||
|
Capital
Stock
Preferred
|
Issued
Common
|
Additional
Paid-In
Capital
|
Retained
Earnings
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Treasury
Stock
|
Total
|
||||||||||||||||||||||
|
Balance, December 31, 2012
|
$ | 4 | $ | 6,715 | $ | 7,894 | $ | 72,531 | $ | (233 | ) | $ | (84 | ) | $ | 86,827 | ||||||||||||
|
Comprehensive income:
|
||||||||||||||||||||||||||||
|
Net income
|
- | - | - | 1,477 | - | - | 1,477 | |||||||||||||||||||||
|
Change in pension plans (a)
|
- | - | - | - | 22 | - | 22 | |||||||||||||||||||||
|
Change in post employment
Benefits (a)
|
- | - | - | - | (159 | ) | - | (159 | ) | |||||||||||||||||||
|
Change in translation adjustment on
non-consolidated foreign
subsidiary, net of tax
|
- | - | - | - | (12 | ) | - | (12 | ) | |||||||||||||||||||
|
Dividends declared
|
- | - | - | (916 | ) | - | - | (916 | ) | |||||||||||||||||||
|
Share-based compensation
|
- | - | 353 | - | - | - | 353 | |||||||||||||||||||||
|
Stock shares reacquired
|
- | - | - | - | - | (15 | ) | (15 | ) | |||||||||||||||||||
|
Balance, March 31, 2013
|
$ | 4 | $ | 6,715 | $ | 8,247 | $ | 73,092 | $ | (382 | ) | $ | (99 | ) | $ | 87,577 | ||||||||||||
|
(a)
|
See
|
|
March 31,
2013
|
December 31,
2012
|
|||||||
|
Finished goods
|
$ | 13,181 | $ | 14,272 | ||||
|
Barreled distillate
|
11,047 | 9,080 | ||||||
|
Raw materials
|
6,467 | 5,959 | ||||||
|
Work in process
|
3,243 | 2,571 | ||||||
|
Maintenance materials
|
4,541 | 4,116 | ||||||
|
Other
|
519 | 534 | ||||||
|
Total
|
$ | 38,998 | $ | 36,532 | ||||
|
•
|
Level 1—quoted prices in active markets for identical assets or liabilities accessible by the reporting entity.
|
|
•
|
Level 2—observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
|
|
•
|
Level 3—unobservable inputs for an asset or liability. Unobservable inputs should only be used to the extent observable inputs are not available.
|
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
ICP’s Operating results:
|
||||||||
|
Net sales (a)
|
$ | 32,850 | $ | 58,053 | ||||
|
Cost of sales and expenses (b)
|
36,080 | 56,925 | ||||||
|
Net income (loss)
|
$ | (3,230 | ) | $ | 1,128 | |||
|
(a)
|
Includes related party sales to MGPI of $2,687 and $15,994 for the quarters ended March 31, 2013 and 2012, respectively.
|
|
(b)
|
Includes depreciation and amortization of $1,170 and $1,259 for the quarters ended March 31, 2013 and 2012, respectively.
|
|
March 31,
2013
|
December 31,
2012
|
|||||||
|
ICP’s Balance Sheet:
|
||||||||
|
Current assets
|
$ | 27,952 | $ | 19,972 | ||||
|
Noncurrent assets
|
18,686 | 19,856 | ||||||
|
Total assets
|
$ | 46,638 | $ | 39,828 | ||||
|
Current liabilities
|
$ | 26,667 | $ | 16,631 | ||||
|
Noncurrent liabilities
|
208 | 203 | ||||||
|
Equity
|
19,763 | 22,994 | ||||||
|
Total liabilities and equity
|
$ | 46,638 | $ | 39,828 | ||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
ICP (30% interest) (a)
|
$ | (969 | ) | $ | 473 | |||
|
DMI (50% interest)
|
27 | (36 | ) | |||||
| $ | (942 | ) | $ | 437 | ||||
|
(a)
|
The Company’s ownership percentage of ICP was 50 percent through February 1, 2012, when the Company sold 20 percent of its investment. From February 2, 2012 through March 31, 2012, and until March 31, 2013, the Company’s ownership percentage in ICP was 30 percent.
|
|
March 31,
2013
|
December 31,
2012
|
|||||||
|
ICP (30% interest)
|
$ | 5,929 | $ | 6,898 | ||||
|
DMI (50% interest)
|
418 | 403 | ||||||
| $ | 6,347 | $ | 7,301 | |||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Continuing Operations:
|
||||||||
|
Net income from continuing operations attributable to shareholders
|
$ | 71 | $ | 1,876 | ||||
|
Less: Amounts allocated to participating securities (nonvested shares and units)
(i)
|
(5 | ) | (141 | ) | ||||
|
Net income from continuing operations attributable to common shareholders
|
$ | 66 | $ | 1,735 | ||||
|
Discontinued Operations:
|
||||||||
|
Discontinued operations attributable to shareholders
|
$ | 1,406 | $ | - | ||||
|
Less: Amounts allocated to participating securities (nonvested shares and units)
(i)
|
( 103 | ) | - | |||||
|
Discontinued operations attributable to common shareholders
|
$ | 1,303 | $ | - | ||||
|
Share information:
|
||||||||
|
Basic weighted average common shares
(ii)
|
16,999,146 | 16,916,304 | ||||||
|
Potential dilutive securities
(iii)
|
- | 3,004 | ||||||
|
Diluted weighted average common shares
|
16,999,146 | 16,919,308 | ||||||
|
Basic earnings per share
|
||||||||
|
Income from continuing operations
|
$ | - | $ | 0.10 | ||||
|
Income from discontinued operations
|
0.08 | - | ||||||
|
Net income
|
$ | 0.08 | $ | 0.10 | ||||
|
Diluted earnings per share
|
||||||||
|
Income from continuing operations
|
$ | - | $ | 0.10 | ||||
|
Income from discontinued operations
|
0.08 | - | ||||||
|
Net income
|
$ | 0.08 | $ | 0.10 | ||||
|
(i)
|
Participating securities include 917,372 and 1,199,661 nonvested restricted shares for the quarters ended March 31, 2013 and 2012, respectively as well as 421,014 and 174,000 restricted share units for the quarters ended March 31, 2013 and 2012, respectively.
|
|
(ii)
|
Under the two-class method, basic weighted average common shares exclude outstanding nonvested participating securities consisting of restricted share awards of 917,372 and 1,199,661 for the quarters ended March 31, 2013 and 2012, respectively.
|
|
(iii)
|
Anti-dilutive shares related to stock options totaled 20,000 and 28,000 for the quarters ended March 31, 2013 and 2012, respectively.
|
|
Quarter Ended
|
|||||||||
|
Classified
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Commodity derivatives
|
Cost of sales
|
$ | 63 | $ | (827 | ) | |||
|
Amount of Gains (Losses)
Recognized in Other
Comprehensive Income on
Derivatives
|
Amount of Gains (Losses)
Reclassified from Accumulated
Other Comprehensive Income into
Earnings
|
|||||||||||||||||
|
Derivatives
in Cash Flow Hedging
Relationship
|
Quarter Ended
March 31,
2013
|
Quarter Ended
March 31,
2012
|
Location of
Losses
Reclassified
from AOCI
into Income
|
Quarter Ended
March 31,
2013
|
Quarter Ended
March 31,
2012
|
|||||||||||||
|
Commodity derivatives
|
- | $ | (286 | ) |
Cost of sales
|
- | $ | (413 | ) | |||||||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Net Sales to Customers
|
||||||||
|
Distillery products
|
$ | 70,804 | $ | 72,485 | ||||
|
Ingredient solutions
|
15,402 | 13,578 | ||||||
|
Other
|
198 | 281 | ||||||
|
Total
|
86,404 | 86,344 | ||||||
|
Depreciation and Amortization
|
||||||||
|
Distillery products
|
2,001 | 1,747 | ||||||
|
Ingredient solutions
|
585 | 650 | ||||||
|
Other
|
20 | 61 | ||||||
|
Corporate
|
362 | 477 | ||||||
|
Total
|
2,968 | 2,935 | ||||||
|
Income (Loss)
from Continuing Operations
before Income Taxes
|
||||||||
|
Distillery products
|
4,318 | 2,686 | ||||||
|
Ingredient solutions
|
1,572 | 1,638 | ||||||
|
Other
|
(90 | ) | (96 | ) | ||||
|
Corporate
|
(5,729 | ) | (6,239 | ) | ||||
|
Gain on sale of assets and joint venture
interest
(i)
|
- | 4,007 | ||||||
|
Total
|
$ | 71 | $ | 1,996 | ||||
|
(i)
|
The Company’s management reporting does not assign or allocate special charges to the Company’s operating segments. For purposes of comparative analysis, the gain on sale of joint venture interest for the quarter ended March 31, 2012 has been excluded from the Company’s segments.
|
|
As of March 31,
2013
|
As of December 31,
2012
|
|||||||
|
Identifiable Assets
|
||||||||
|
Distillery products
|
$ | 106,800 | $ | 107,140 | ||||
|
Ingredient solutions
|
28,937 | 27,038 | ||||||
|
Other
|
- | 1,247 | ||||||
|
Corporate
|
25,477 | 27,746 | ||||||
|
Total
|
$ | 161,214 | $ | 163,171 | ||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Service cost
|
$ | 33 | $ | 56 | ||||
|
Interest cost
|
43 | 59 | ||||||
|
Amortization of prior service cost
|
(167 | ) | (4 | ) | ||||
|
Amortization of net actuarial loss
|
8 | - | ||||||
|
Total post-retirement benefit cost / (income)
|
$ | (83 | ) | $ | 111 | |||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Interest cost
|
$ | 21 | $ | 51 | ||||
|
Expected return on plan assets
|
(29 | ) | (57 | ) | ||||
|
Amortization of net actuarial loss
|
17 | 28 | ||||||
|
Total pension benefit cost / (income)
|
$ | 9 | $ | 22 | ||||
|
Stock options granted but not exercised
|
20,000 | |||
|
Restricted stock to non-employees (authorized but not granted)
|
39,797 | |||
|
Restricted stock to employees and executives (authorized but not granted)
|
1,348,300 | |||
|
Total
|
1,408,097 |
|
(i)
|
(ii)
|
(iii) = (i) - (ii)
|
||||||||||
|
Description
|
Gross
Amounts of
Recognized
Assets
(Liabilities)
|
Gross
Amounts
offset in the
Balance Sheet
|
Net Amounts of
Assets (Liabilities)
presented in the
Balance Sheet
|
|||||||||
|
March 31, 2013
|
||||||||||||
|
Investment in IRBs
|
$ | 7,000 | $ | 7,000 | $ | - | ||||||
|
Capital lease obligation
|
$ | (7,000 | ) | $ | (7,000 | ) | $ | - | ||||
|
December 31, 2012
|
||||||||||||
|
Investment in IRBs
|
$ | 7,000 | $ | 7,000 | $ | - | ||||||
|
Capital lease obligation
|
$ | (7,000 | ) | $ | (7,000 | ) | $ | - | ||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Distillery products
|
||||||||
|
Net Sales
|
$ | 70,804 | $ | 72,485 | ||||
|
Pre-Tax Income
|
4,318 | 2,686 | ||||||
|
Ingredient solutions
|
||||||||
|
Net Sales
|
15,402 | 13,578 | ||||||
|
Pre-Tax Income
|
1,572 | 1,638 | ||||||
|
Other
|
||||||||
|
Net Sales
|
198 | 281 | ||||||
|
Pre-Tax Loss
|
(90 | ) | (96 | ) | ||||
|
March 31,
|
December 31,
|
|||||||
|
2013
|
2012
|
|||||||
|
Cash and cash equivalents
|
$ | - | $ | - | ||||
|
Working capital
|
48,001 | 48,320 | ||||||
|
Amounts available under lines of credit
|
25,583 | 18,381 | ||||||
|
Credit facility, notes payable and long-term debt
|
28,191 | 32,744 | ||||||
|
Stockholders’ equity
|
87,577 | 86,827 | ||||||
|
Quarter Ended
|
||||||||
|
March 31,
|
March 31,
|
|||||||
|
2013
|
2012
|
|||||||
|
Depreciation and amortization
|
$ | 2,968 | $ | 2,935 | ||||
|
Capital expenditures
|
798 | 484 | ||||||
|
Cash flows from operations
|
2,554 | (10,971 | ) | |||||
|
Quarter Ended
|
||||||||
|
March 31,
|
March 31,
|
|||||||
|
2013
|
2012
|
|||||||
|
Cash flows provided by (used for):
|
||||||||
|
Operating activities
|
$ | 2,554 | $ | (10,971 | ) | |||
|
Investing activities
|
1,999 | 10,351 | ||||||
|
Financing activities
|
(4,553 | ) | 237 | |||||
|
Decrease in cash and cash equivalents
|
- | (383 | ) | |||||
|
Cash and cash equivalents at beginning of year
|
- | 383 | ||||||
|
Cash and cash equivalents at end of period
|
$ | - | $ | - | ||||
|
Quarter Ended
|
||||||||
|
March 31,
2013
|
March 31,
2012
|
|||||||
|
Cash Flows from Operating Activities
|
||||||||
|
Net income
|
$ | 1,477 | $ | 1,876 | ||||
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
||||||||
|
Depreciation and amortization
|
2,968 | 2,935 | ||||||
|
Gain on sale of bioplastics manufacturing business
|
(1,453 | ) | - | |||||
|
Gain on sale of joint venture interest
|
- | (4,055 | ) | |||||
|
Loss on sale of assets
|
- | 48 | ||||||
|
Share based compensation
|
353 | 353 | ||||||
|
Equity in (earnings) loss
|
942 | (437 | ) | |||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Restricted cash
|
12 | 1,454 | ||||||
|
Receivables, net
|
980 | (7,984 | ) | |||||
|
Inventory
|
(2,539 | ) | (3,236 | ) | ||||
|
Prepaid expenses
|
(654 | ) | (409 | ) | ||||
|
Refundable income taxes
|
(38 | ) | 120 | |||||
|
Accounts payable
|
3,603 | (1,880 | ) | |||||
|
Accounts payable to affiliate, net
|
(3,287 | ) | (1,380 | ) | ||||
|
Accrued expenses
|
529 | 904 | ||||||
|
Change in derivatives
|
- | 1,131 | ||||||
|
Deferred credit
|
(97 | ) | (150 | ) | ||||
|
Accrued retirement health and life insurance benefits and other noncurrent liabilities
|
(242 | ) | (261 | ) | ||||
|
Net cash provided by (used in) operating activities
|
$ | 2,554 | $ | (10,971 | ) | |||
|
·
|
for the quarter ended March 31, 2013, a decrease in accounts payable to affiliate of $3,287 compared to a decrease of $1,380 for the quarter ended March 31, 2012. This is due to reduced purchases from ICP; and
|
|
·
|
for the quarter ended March 31, 2013, change in derivatives had no cash impact compared to the quarter ended March 31, 2012 when change in derivatives provided cash of $1,131. During the quarter ended March 31, 2013 we had no derivatives designated as cash flow hedges whereas during the quarter ended March 31, 2012, we designated our remaining cash flow hedges; and
|
|
·
|
for the quarter ended March 31, 2013, our pledge requirement decreased $12, given that we no longer have any open market positions. This compares to an decrease in the pledge requirement of $1,454 for the quarter ended March 31, 2012.
|
|
(a) Total
Number of
Shares (or
Units)
Purchased
|
(b) Average
Price Paid
per Share (or
Unit)
|
(c) Total
Number of
Shares (or
Units)
Purchased as
Publicly
Announced
Plans or
Programs
|
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
|
|||||||||||||||
|
January 1, 2013 through January 31, 2013
|
- | - | $ | - | ||||||||||||||
|
February 1, 2013 through February 28, 2013
|
- | - | ||||||||||||||||
|
March 1, 2013 through March 31, 2013
|
3,756 | (1) | $ | 4.14 | (1) | - | ||||||||||||
|
Total
|
3,756 | - | ||||||||||||||||
|
(1)
|
Aggregate number of shares repurchased to satisfy withholding tax obligations under restricted stock that vested during the month.
|
|
Exhibit Number
|
Description of Exhibit
|
|
2.1
|
Agreement of Merger and Plan of Reorganization, dated as of January 3, 2012, by and among MGPI Processing, Inc. (formerly MGP Ingredients, Inc.), MGP Ingredients, Inc. (formerly MGPI Holdings, Inc.) and MGPI Merger Sub, Inc. (Incorporated by reference to Exhibit 2 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
3.1
|
Articles of Incorporation of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed January 5, 2012) (File number 000-17196))
|
|
3.2
|
Certificate of Amendment to Articles of Incorporation of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
3.3
|
Bylaws of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
*31.1
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)
|
|
*31.2
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
|
|
*32.1
|
Certification of Chief Executive Officer furnished pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
|
|
*32.2
|
Certification of Chief Financial Officer furnished pursuant to Rule 13a-4(b) and 18 U.S.C. 1350
|
|
*101
|
The following financial information from MGP Ingredients, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in XBRL (Extensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, (iii) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2012, and (iv) the Notes to Condensed Consolidated Financial Statements. In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise this Exhibit 101 shall be deemed “furnished” and not “filed.”
|
|
*Filed herewith
|
|
Date: May 6, 2013
|
By |
/s/ Timothy W. Newkirk
|
|
Timothy W. Newkirk, President and Chief Executive Officer
|
||
|
Date: May 6, 2013
|
By |
/s/ Don Tracy
|
|
Don Tracy
Vice President and Chief Financial
Officer (Principal Financial and
Accounting Officer)
|
|
Exhibit Number
|
Description of Exhibit
|
|
2.1
|
Agreement of Merger and Plan of Reorganization, dated as of January 3, 2012, by and among MGPI Processing, Inc. (formerly MGP Ingredients, Inc.), MGP Ingredients, Inc. (formerly MGPI Holdings, Inc.) and MGPI Merger Sub, Inc. (Incorporated by reference to Exhibit 2 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
3.1
|
Articles of Incorporation of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed January 5, 2012) (File number 000-17196))
|
|
3.2
|
Certificate of Amendment to Articles of Incorporation of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
3.3
|
Bylaws of MGP Ingredients, Inc. (Incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed January 5, 2012 (File number 000-17196))
|
|
*31.1
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)
|
|
*31.2
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
|
|
*32.1
|
Certification of Chief Executive Officer furnished pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
|
|
*32.2
|
Certification of Chief Financial Officer furnished pursuant to Rule 13a-4(b) and 18 U.S.C. 1350
|
|
*101
|
The following financial information from MGP Ingredients, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in XBRL (Extensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, (iii) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2012, and (iv) the Notes to Condensed Consolidated Financial Statements. In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise this Exhibit 101 shall be deemed “furnished” and not “filed.”
|
|
*Filed herewith
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|